A phase I, placebo controlled, dose escalation safety andpharmacokinetic study of Topical Endoxifen in healthy male volunteers.
Phase of Trial: Phase I
Latest Information Update: 26 Jun 2018
At a glance
- Drugs Endoxifen (Primary)
- Indications Gynaecomastia
- Focus Adverse reactions
- Sponsors Atossa Genetics
- 26 Jun 2018 According to an Atossa Genetics media release, the company plans to announce preliminary results from this trial in the third quarter of 2018.
- 20 Jun 2018 According to an Atossa Genetics media release, the company has completed dosing and clinical visits in its Phase 1 study of its proprietary topical Endoxifen in men. It is proceeding with analysis of blood samples, data collection and analysis.
- 20 Jun 2018 According to an Atossa Genetics media release, status changed from recruiting to completed.